Supravitz Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 21-12-2024
- Paid Up Capital ₹ 3.00 Cr
as on 21-12-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.71 Cr
as on 21-12-2024
- Revenue 112.62%
(FY 2022)
- Profit 173.49%
(FY 2022)
- Ebitda 70.09%
(FY 2022)
- Net Worth 294.57%
(FY 2022)
- Total Assets 35.59%
(FY 2022)
About Supravitz Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹11.71 Cr.
Rajesh Agarwal, Dipak Tibrewal, and Pradeep Sahal serve as directors at the Company.
- CIN/LLPIN
U15549GJ2017PTC098833
- Company No.
098833
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Aug 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Supravitz Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Agarwal  | Director | 25-Aug-2017 | Current |
| Dipak Tibrewal | Director | 25-Aug-2017 | Current |
| Pradeep Sahal | Director | 25-Aug-2017 | Current |
Financial Performance of Supravitz Lifesciences.
Supravitz Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 112.62% increase. The company also saw a substantial improvement in profitability, with a 173.49% increase in profit. The company's net worth Soared by an impressive increase of 294.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Supravitz Lifesciences?
Unlock access to Supravitz Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Doleshwor Pharmaceuticals Private LimitedActive 9 years 2 monthsRajesh Agarwal and Dipak Tibrewal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Jun 2020 | ₹7.51 Cr | Open |
Vijaya Bank Creation Date: 14 Feb 2018 | ₹2.10 Cr | Open |
Vijaya Bank Creation Date: 23 Jan 2018 | ₹2.10 Cr | Open |
How Many Employees Work at Supravitz Lifesciences?
Unlock and access historical data on people associated with Supravitz Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Supravitz Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supravitz Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
